Loading
A phase 1 trial of DNX-2440 run by DNAtrix, Inc., suspended.
DNX-2440 for Resectable Colorectal Liver Metastasis is a phase 1 interventional study registered as NCT04714983 by DNAtrix, Inc., with 30 participants planned, started 2021-02-15. Conditions recorded: Liver Metastases, Liver Metastasis Colon Cancer, Colorectal Cancer, Breast Cancer, Gastric Cancer, Periampullary Cancer, Melanoma, Renal Cell Cancer, Sarcoma, Squamous Cell Carcinoma and Gastrointestinal Stromal Tumors. Interventions recorded: DNX-2440.
Shares DNAtrix, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares DNAtrix, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares DNAtrix, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, Breast cancer (all types), Metastatic cancer (cancer that has spread), Colorectal cancer and the tag pipeline.
Shares Sarcomas (soft tissue, bone, GIST), Gastric & gastro-oesophageal junction cancer, Colorectal cancer and the tag pipeline.
Shares Renal cell carcinoma, Gastric & gastro-oesophageal junction cancer, Melanoma, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/